Skip to main content
Top
Published in: Diabetologia 7/2006

01-07-2006 | Article

What determines the cost-effectiveness of diabetes screening?

Authors: C. Glümer, M. Yuyun, S. Griffin, D. Farewell, D. Spiegelhalter, A. L. Kinmonth, N. J. Wareham

Published in: Diabetologia | Issue 7/2006

Login to get access

Abstract

Aims/hypothesis

The cost-effectiveness of screening for diabetes is unknown but has been modelled previously. None of these models has taken account of uncertainty. We aimed to describe these uncertainties in a model where the outcome was CHD risk.

Subjects and methods

Our model used population data from the Danish Inter99 study, and simulations were run in a theoretical population of 1,000,000 individuals. CHD risk was estimated using the UK Prospective Diabetes Study (UKPDS) risk engine, and risk reduction from published randomised clinical trials. Probabilistic sensitivity analysis was used to provide confidence intervals for modelled outputs. Uncertain parameter values were independently simulated from distributions derived from existing literature and deterministic sensitivity analysis performed using multiple model runs under different strategy choices and using extreme parameter estimates.

Results

In the least conservative model (low costs and multiplicative risk reduction for combined treatments), the 95% confidence interval of the incremental cost-effectiveness ratio varied from £23,300–82,000. The major contributors to this uncertainty were treatment risk reduction model parameters: the risk reduction for hypertension treatment and UKPDS risk model intercept. Overall cost-effectiveness ratio was not sensitive to decisions about which groups to screen, nor the costs of screening or treatment. It was strongly affected by assumptions about how treatments combine to reduce risk.

Conclusions/interpretation

Our model suggests that there is considerable uncertainty about whether or not screening for diabetes would be cost-effective. The most important but uncertain parameter is the effect of treatment. In addition to directly influencing current policy decisions, health care modelling can identify important unknown or uncertain parameters that may be the target of future research.
Literature
1.
go back to reference King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef
2.
go back to reference Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617–621CrossRef Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617–621CrossRef
3.
go back to reference Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for Type 2 diabetes—should it be now? Diabet Med 20:175–181PubMedCrossRef Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for Type 2 diabetes—should it be now? Diabet Med 20:175–181PubMedCrossRef
4.
go back to reference Wareham NJ, Griffin SJ (2001) Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 322:986–988PubMedCrossRef Wareham NJ, Griffin SJ (2001) Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 322:986–988PubMedCrossRef
5.
go back to reference Hofer TP, Vijan S, Hayward RA (2000) Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 16:822–833PubMedCrossRef Hofer TP, Vijan S, Hayward RA (2000) Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 16:822–833PubMedCrossRef
6.
go back to reference Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M (2004) Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140:689–699PubMed Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M (2004) Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140:689–699PubMed
7.
8.
go back to reference Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548–551PubMedCrossRef Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548–551PubMedCrossRef
9.
go back to reference Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 12:30–35PubMedCrossRef Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 12:30–35PubMedCrossRef
10.
go back to reference Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101:671–679PubMedCrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101:671–679PubMedCrossRef
11.
go back to reference Huang ES, Meigs JB, Singer DE (2001) The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633–642PubMedCrossRef Huang ES, Meigs JB, Singer DE (2001) The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633–642PubMedCrossRef
12.
go back to reference Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:S6–S11PubMedCrossRef Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:S6–S11PubMedCrossRef
13.
go back to reference Joint Formulary Committee (2002) British National Formulary. British Medical Association, and Royal Pharmaceutical Society of Great Britain, London Joint Formulary Committee (2002) British National Formulary. British Medical Association, and Royal Pharmaceutical Society of Great Britain, London
14.
go back to reference Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V et al (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V et al (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
15.
go back to reference Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
16.
go back to reference Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a danish population: the inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a danish population: the inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef
17.
go back to reference Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehabil 10:377–386PubMedCrossRef Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehabil 10:377–386PubMedCrossRef
18.
go back to reference Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. 1999. World Health Organization, Geneva 1999. WHO/NCD/NCS/99.2 Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. 1999. World Health Organization, Geneva 1999. WHO/NCD/NCS/99.2
19.
go back to reference CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention (1998) The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757–1763CrossRef CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention (1998) The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757–1763CrossRef
20.
go back to reference Chen TH-H, Yen MF, Tung TH (2001) A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract 54:37–42CrossRef Chen TH-H, Yen MF, Tung TH (2001) A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract 54:37–42CrossRef
21.
go back to reference Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735–744PubMedCrossRef Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735–744PubMedCrossRef
22.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
23.
go back to reference Type 2-diabetes i almen praksis, en evidensbaseret vejledning. 2004. Dansk Selskab for Almen Medicin Type 2-diabetes i almen praksis, en evidensbaseret vejledning. 2004. Dansk Selskab for Almen Medicin
24.
go back to reference American Diabetes Association (2006) Standards of medical care in diabetes—2006. Diabetes Care 29:S4–S42 American Diabetes Association (2006) Standards of medical care in diabetes—2006. Diabetes Care 29:S4–S42
25.
go back to reference Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef
26.
go back to reference Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef
Metadata
Title
What determines the cost-effectiveness of diabetes screening?
Authors
C. Glümer
M. Yuyun
S. Griffin
D. Farewell
D. Spiegelhalter
A. L. Kinmonth
N. J. Wareham
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0248-x

Other articles of this Issue 7/2006

Diabetologia 7/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.